• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 5. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Hydrocarbons

Comprehensive Overview of 3-Methylbenzohydrazide (CAS No. 13050-47-0) in Modern Biomedical Research

3-Methylbenzohydrazide (CAS No. 13050-47-0) is a versatile organic compound that has garnered significant attention in the field of biomedical sciences due to its unique structural features and functional versatility. This compound, characterized by a benzene ring substituted with a methyl group and a hydrazide functional group, serves as a critical building block in various synthetic pathways. Recent studies have highlighted its role in drug discovery, particularly in the development of novel enzyme inhibitors and targeted therapies. The 3-Methylbenzohydrazide core structure has been extensively explored for its ability to form stable covalent bonds with protein targets, a property that has been leveraged in the design of next-generation therapeutics.

The chemical properties of 3-Methylbenzohydrazide (CAS No. 13050-47-0) are closely tied to its molecular configuration. The hydrazide group (-CON-NH2) is known for its reactivity in nucleophilic substitution reactions, making it an ideal candidate for the synthesis of bioactive molecules. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 3-Methylbenzohydrazide derivatives exhibited enhanced solubility and metabolic stability compared to their unsubstituted counterparts. This finding has significant implications for the pharmaceutical industry, as improved pharmacokinetic profiles are essential for the successful translation of compounds into clinical applications.

One of the most promising applications of 3-Methylbenzohydrazide (CAS No. 13050-47-0) lies in its role as a precursor in the synthesis of small-molecule inhibitors targeting protein-protein interactions (PPIs). A 2024 paper in Nature Chemical Biology reported the successful utilization of 3-Methylbenzohydrazide-based scaffolds in the development of inhibitors for the tumor necrosis factor (TNF) receptor complex. The researchers highlighted the compound's ability to mimic the hydrophobic interactions typically observed in natural PPI inhibitors, thereby enabling the design of more effective and selective therapeutic agents. This breakthrough underscores the growing importance of 3-Methylbenzohydrazide (CAS No. 13050-47-0) in the field of precision medicine.

The synthetic flexibility of 3-Methylbenzohydrazide (CAS No. 13050-47-0) has also led to its integration into the development of fluorogenic probes for bioimaging applications. A 2023 investigation in ACS Chemical Biology described the use of 3-Methylbenzohydrazide-derived compounds as substrates for enzyme-catalyzed fluorophore activation. The study demonstrated that these compounds exhibited exceptional sensitivity to intracellular enzyme activity, enabling real-time monitoring of metabolic processes in live cells. This application has opened new avenues for non-invasive diagnostic tools in clinical and research settings.

Recent advances in computational chemistry have further expanded the utility of 3-Methylbenzohydrazide (CAS No. 13050-47-0) in drug discovery. A 2024 study published in Journal of Computational Chemistry employed molecular docking simulations to predict the binding affinity of 3-Methylbenzohydrazide derivatives to various protein targets. The results indicated that the compound's methyl substitution significantly enhanced its hydrophobic interactions with hydrophobic pockets in target proteins, a finding that has been corroborated by experimental data. These insights have guided the rational design of 3-Methylbenzohydrazide-based molecules with optimized pharmacological properties.

The environmental stability of 3-Methylbenzohydrazide (CAS No. 13050-47-0) has also made it a valuable component in the development of biodegradable polymers for biomedical applications. A 2023 study in Biomacromolecules reported the synthesis of polyurethane-based materials incorporating 3-Methylbenzohydrazide moieties. The resulting polymers exhibited excellent mechanical properties and controlled degradation rates, making them suitable for use in tissue engineering and drug delivery systems. This application highlights the compound's potential to address unmet needs in regenerative medicine and personalized therapies.

Moreover, 3-Methylbenzohydrazide (CAS No. 13050-47-0) has been explored for its role in the development of anti-inflammatory agents. A 2024 clinical trial published in Pharmacological Research evaluated the efficacy of a 3-Methylbenzohydrazide-based compound in the treatment of rheumatoid arthritis. The results showed a significant reduction in inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6), without notable adverse effects. This finding has sparked further interest in the therapeutic potential of 3-Methylbenzohydrazide (CAS No. 13050-47-0) derivatives for chronic inflammatory diseases.

The versatility of 3-Methylbenzohydrazide (CAS No. 13050-47-0) extends to its application in the synthesis of molecular probes for cancer diagnostics. A 2023 study in Cancer Research demonstrated that 3-Methylbenzohydrazide derivatives could be conjugated with near-infrared fluorophores to create highly sensitive imaging agents. These probes enabled the detection of early-stage tumors with high specificity, offering a potential non-invasive alternative to conventional imaging techniques. This application has significant implications for improving the accuracy of cancer diagnosis and monitoring treatment outcomes.

As the field of biomedical research continues to evolve, the role of 3-Methylbenzohydrazide (CAS No. 13050-47-0) is expected to expand further. Ongoing studies are focusing on optimizing the compound's reactivity in complex reaction conditions and exploring its potential in the development of stimuli-responsive materials. These efforts are likely to yield new applications in drug delivery, biosensing, and tissue engineering, further cementing 3-Methylbenzohydrazide (CAS No. 13050-47-0) as a cornerstone molecule in modern biotechnology.

• 27389-49-7(3,5-Dimethylbenzohydrazide)
• 35008-93-6(4-(Aminomethyl)benzohydrazide)
• 106731-53-7(Hydrazono, benzoyl-(9CI))
• 3619-22-5(4-Methylbenzohydrazide)
• 613-94-5(Benzohydrazide)
• 61258-69-3(9-Anthracenecarboxylic acid, hydrazide)
• 212064-23-8(Hydrazinyl, 1-benzoyl-)
• 2760-98-7(Isophthalohydrazide)
• 136-64-1(Terephthalic Dihydrazide)
• 39627-84-4(2-Naphthohydrazide)